Vical Incorporated Share Price Nasdaq
Equities
US9256021042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/03 | Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index | CI |
Sales 2022 | 6.94M 579M | Sales 2023 | 8.01M 668M | Capitalization | 5.25M 438M |
---|---|---|---|---|---|
Net income 2022 | -21M -1.75B | Net income 2023 | -5M -417M | EV / Sales 2022 | -0.59 x |
Net cash position 2022 | 8.63M 720M | Net cash position 2023 | 10.87M 907M | EV / Sales 2023 | -0.7 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.4% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01/20/01 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 01/16/01 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |